Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation

NCT02713282 is registered in ClinicalTrials.gov with Janssen-Cilag Ltd. as lead sponsor.

NCT NCT02713282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02713282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
Lead sponsor
Janssen-Cilag Ltd.
Phase
Phase 3
Overall status
Completed
Start date
April 28, 2016
Completion date
March 26, 2018
Enrollment
306 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia